At Tailor Made Compounding, we understand the importance of providing alternative solutions, especially during drug shortages that may negatively impact patient outcomes. Currently, commercially available semaglutide products are listed on the FDA Drug Shortage website – with limited availability projected through December 2023.

As a reminder, the FDA states that if a drug is listed as “currently in shortage,” it may be compounded. Both commercial products containing semaglutide have been on the drug shortage list since March of 2022 – 18 months in which patients have had limited access to these FDA-approved medications prescribed by their physicians. Fortunately, compounding pharmacies offer a solution by temporarily compounding semaglutide to meet demand, facilitating the continuation of uninterrupted patient care.

The FDA allows compounding of drugs on shortage to ensure patients have continued access to medications that, in their prescriber’s judgment, are necessary for continuity of care. Once removed from the shortage list, compounding pharmacies will have no basis to compound semaglutide and will transition to only offering commercial products containing semaglutide. In the interim, compounding pharmacies may step up as providers for patients in need of these essential therapies.

While we anticipate an update from the FDA regarding this matter by the end of December, we remain dedicated to upholding our standards of care and patient safety by adhering to these guidelines.

For more information, please find additional resources linked below:

A4PC’s Statement on Rules Governing Compounding

Tailor Made Compounding Discusses How to Ensure Your Compounding Pharmacy Partner is Compliant